Health Outcomes, Epidemiology and Biostatistics Consulting

Perisphere RWE Mission

We make scientific discoveries and improve health outcomes by applying advanced epidemiology and statistical tools to generate real-world evidence

Dr. Paul Muntner

Founder, Perisphere real-world evidence, LLC.

Dr. Paul Muntner has over 20 years of experience conducting pharmacoepidemiology research. He earned a Master’s of Health Science in Biostatistics and Doctor of Philosophy in Epidemiology from the Johns Hopkins Bloomberg School of Public Health. From 2000 to 2023, he served as a faculty member at Tulane University School of Public Health and Tropical Medicine, Mount Sinai School of Medicine, and the University of Alabama at Birmingham (UAB) School of Public Health. At UAB, he served as the Co-director of the Pharmacoepidemiology and Economics Research Unit and Associate Dean for Research at the School of Public Health. Dr. Muntner has led studies across the drug lifecycle including providing data to support FDA filings for initial approval and post-approval label expansion. He has published over 600 peer-reviewed journal articles.

Pharmacoepidemiology Expertise

  • Over 20 years experience generating real-world evidence (RWE).
  • Government experience – Acting Chief Science Officer for the Centers for Disease Control and Prevention (CDC).
  • Analyzing large claims datasets for FDA filings and regulatory requirements.
  • Implementing and leading data coordinating centers.
  • Member and chair of guideline and Scientific Statement committees.
  • Over 700 peer-reviewed publications in top medical journals (cited >100,000).

We Move Research
Beyond Publications

  • Primary data collection
  • Advanced data analytics
  • Cost-effectiveness analyses
  • Guideline implementation
  • Policy modeling
  • Engagement with key opinion leaders
  • Engagement with policy makers

Project Examples

Staging and clean room: Constructs designed to facilitate transparency and reduce bias in comparative analyses of real-world data.

Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: A narrative review.

Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization

Development of algorithms for identifying fatal cardiovascular disease in Medicare claims.

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

We Have Experience Providing
Evidence Across a Product Life Cycle

Pre-Market

  • Population sizing
  • Unmet treatment needs
  • Cost analyses
  • Assessing/guidance on trial inclusion criteria
  • Background adverse event rates

Post Approval

  • Comparative effectiveness
  • Adherence
  • Label expansion
  • Evaluation of possible safety signals

Our Capabilities

  • Study design and protocol development
  • Questionnaire development
  • Database development and implementation
  • Statistical analysis and machine learning
  • Qualitative data collection
  • Data linkage and claims data algorithm validation
  • Systematic reviews
  • Data visualization

Why Work With Us

Collaborative, engaging leaders as partners

Innovative, using advanced scientific methods

Productive, achieving high scientific productivity

Impactful, disseminating broadly through publications